Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration

1. Galapagos has entered a $665 million biobucks collaboration with Adaptimmune for the development of uza-cel, a MAGE-A4 TCR T-cell therapy.
2. The deal was announced after market close on Thursday and involves a multi-pronged agreement.
3. Uza-cel is being developed by Adaptimmune for various indications.
4. The partnership provides Adaptimmune with significant financing, helping it avoid a potential financing cliff.
5. The collaboration marks a significant step in the development of next-generation T-cell therapies.